Analysts Set Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Price Target at $55.00

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been given a consensus recommendation of “Moderate Buy” by the five analysts that are currently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $55.00.

Several analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Tuesday, April 21st. Jefferies Financial Group raised Silence Therapeutics to a “strong-buy” rating in a research note on Wednesday, March 18th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 target price on shares of Silence Therapeutics in a research note on Friday, March 13th. Finally, William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a research note on Monday, March 2nd.

Silence Therapeutics Price Performance

Shares of SLN opened at $6.80 on Friday. The firm has a market cap of $321.23 million, a P/E ratio of -4.28 and a beta of 1.52. The stock has a 50 day simple moving average of $6.52 and a two-hundred day simple moving average of $6.10. Silence Therapeutics has a 1 year low of $4.19 and a 1 year high of $8.40.

Silence Therapeutics (NASDAQ:SLN) last issued its earnings results on Friday, May 8th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.14). The firm had revenue of $0.42 million during the quarter, compared to analysts’ expectations of $1.26 million. Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%. On average, equities analysts anticipate that Silence Therapeutics will post -1 earnings per share for the current year.

Institutional Trading of Silence Therapeutics

Institutional investors have recently made changes to their positions in the stock. EHP Funds Inc. purchased a new stake in shares of Silence Therapeutics during the third quarter valued at approximately $55,000. XTX Topco Ltd purchased a new stake in shares of Silence Therapeutics during the fourth quarter valued at approximately $71,000. China Universal Asset Management Co. Ltd. boosted its stake in shares of Silence Therapeutics by 65.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,653 shares of the company’s stock valued at $83,000 after purchasing an additional 5,421 shares during the period. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the second quarter valued at approximately $115,000. Finally, Citadel Advisors LLC purchased a new stake in shares of Silence Therapeutics during the third quarter valued at approximately $112,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

About Silence Therapeutics

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.